Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1

International Clinical Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 199-203

  Secher, Anna ^a,c   Bukh, Jens ^b   Bock, Camilla ^b   Koefoed, Pernille ^a   Rasmussen, Henrik Berg ^a   Werge, Thomas ^a   Kessing, Lars Vedel ^b   Mellerup, Erling ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Antidepressive agents; Case only study; Catechol O methyltransferase; Polymorphism; Side effects; Tryptophan hydroxylase; Weight gain

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMT GENE; DEPRESSION; DISEASE PREDISPOSITION; FEMALE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HTR2C GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SLC6A4 GENE; TPH1 GENE; UDVALG FOR KLINISKE UNDERSOGELSER SIDE EFFECT RATING SCALE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE; WEIGHT GAIN;

EID: 67651227422     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832d6be2     Document Type: Article

References (36)

1. Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E (2008). Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism 57:708-711.
2. Baptista T, Parada M, Hernandez L (1987). Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399-405.
3. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, Roehrs T, et al. (2008). Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33: 924-932.
4. Berken GH, Weinstein DO, Stern WC (1984). Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 7:133-138.
5. Bouchard JM, Strub N, Nil R (1997). Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial. J Affect Disord 46:51-58.
6. Christiansen L, Tan Q, Iachina M, Bathum L, Kruse TA, McGue M, et al. (2007). Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry 61: 223-230.
7. Cooper JR, Melcer I (1961). The enzymic oxidation of tryptophan to 5-hydroxytryptophan in the biosynthesis of serotonin. J Pharmacol Exp Ther 132:265-268.
8. De Vry J, Schreiber R (2000). Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 24:341-353.
9. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, et al. (2005). Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 134B:76-78.
10. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA (2007). Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 27:451-458.
11. Greenwood PM, Parasuraman R (2003). Normal genetic variation, cognition, and aging. Behav Cogn Neurosci Rev 2:278-306.
12. Heisler LK, Chu HM, Tecott LH (1998). Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci 861:74-78.
13. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmacher T (2004). Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 38:485-489.
14. Hosmer DW, Lemeshow S (2000). Applied logistic regression. New York: John Wiley & Sons.
15. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783-792.
16. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, et al. (1997). Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 247:297-302.
17. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
18. Lambert PD, Wilding JP, al-Dokhayel AA, Bohuon C, Comoy E, Gilbey SG, et al. (1993). A role for neuropeptide-Y, dynorphin, and noradrenaline in the central control of food intake after food deprivation. Endocrinology 133:29-32.
19. Leibowitz SF, Alexander JT (1998). Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 44:851-864.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100.
21. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100:6186-6191.
22. Munk-Jorgensen P, Mortensen PB (1997). The danish psychiatric central register. Dan Med Bull 44:82-84.
23. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF (2004). Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61:1163-1169.
24. Palmiter RD (2007). Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30:375-381.
25. Pijl H, Meinders AE (1996). Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf14:329-342.
26. Pi-Sunyer FX (1993). Medical hazards of obesity. Ann Intern Med 119:655-660.
27. Popp J, Leucht S, Heres S, Steimer W (2006). Serotonin transporter polymorphisms and side effects in antidepressant therapy - a pilot study. Pharmacogenomics 7:159-166.
28. Posternak MA, Young D, Sheeran T, Chelminski I, Franklin CL, Zimmerman M (2004). Assessing past treatment history: test-retest reliability of the treatment response to antidepressant questionnaire. J Nerv Ment Dis 192:95-102.
29. Purcell S, Cherny SS, Sham PC (2003). Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149-150.
30. Rasmussen HB, Werge TM (2007). Novel procedure for genotyping of the human serotonin transporter gene-linked polymorphic region (5-HTTLPR) - a region with a high level of allele diversity. Psychiatr Genet 17:287-291.
31. Reynolds GP, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086-2087.
32. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, et al. (2007). Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 22:137-143.
33. Sussman N, Ginsberg DL, Bikoff J (2001). Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 62:256-260.
34. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. (1995). Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546.
35. Templeman LA, Reynolds GP, Arranz B, San L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genom 15:195-200.
36. Wang GJ, Volkow ND, Fowler JS (2002). The role of dopamine in motivation for food in humans: implications for obesity. Expert Opin Ther Targets 6:601-609.